Nicol Christophe, Raj Leela, Guillerm Gaëlle, Couturaud Francis, Eveillard Jean-Richard, Pan-Petesch Brigitte
Service d'Hématologie Institut de Cancéro-Hématologie EA3878 (GETBO) CHU Brest Univ Brest Brest France.
Faculty of Heath Science McMaster University Hamilton ON Canada.
Clin Case Rep. 2020 Mar 9;8(5):900-904. doi: 10.1002/ccr3.2770. eCollection 2020 May.
Acquired von Willebrand syndrome is a rare bleeding disorder often secondary to an underlying lymphoproliferative disorder. We report a case in whom response of both the acquired von Willebrand syndrome and smoldering multiple myeloma persist 14 months after daratumumab treatment discontinuation.
获得性血管性血友病综合征是一种罕见的出血性疾病,通常继发于潜在的淋巴增殖性疾病。我们报告了一例患者,在达雷妥尤单抗治疗停药14个月后,获得性血管性血友病综合征和冒烟型多发性骨髓瘤均持续缓解。